, Volume 32, Issue 5, pp 296–303 | Cite as

Salicylate Inhibits Macrophage-Secreted Factors Induced Adipocyte Inflammation and Changes of Adipokines in 3T3-L1 Adipocytes

  • Yuan An
  • Kang Liu
  • Yuan Zhou
  • Baolin Liu


Antidiabetic effects of salicylates have been known for years, however the cellular and molecular mechanisms of the hypoglycemic activity are not well elucidated. We examined the effects of salicylate on inflammation-related changes in gene or/and protein expressions of several adipokines in 3T3-L1 adipocytes and of LPS-induced inflammatory factors in RAW 264.7 cell. Especially, we focused our attention on the cross-talk between the macrophages and adipocytes. Exposure to RAW-CM medium resulted in an increase in the gene expression or/and protein secretion of TNF-α, IL-6 and resistin, and at the same time, a decrease in the gene expression of PPARγ and adiponectin in 3T3-L1 adipocytes. Salicylate effectively reversed these changes, and up-regulated glucose consumption in adipocytes. We also found salicylate inhibited phosphorylation of NF-κB in RAW-CM-stimulated adipocytes. We conclude salicylate blocks inflammatory process in the pathogenesis of inflammation-related insulin resistance.


salicylates adipokines adipocytes macrophage insulin resistance 



This study was supported by grants from the Fund of Jiangsu Science Foundation of China (BK200717).


  1. 1.
    Xu, H., G. T. Barnes, Q. Yang, G. Tan, D. Yang, C. J. Chou, J. Sole, A. Nichols, J. S. Ross, L. A. Tartag, and H. Chen. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821–1830.PubMedGoogle Scholar
  2. 2.
    Hotamisligil, G. S. 2006. Inflammation and metabolic disorders. Nature 444-14:860–867.CrossRefGoogle Scholar
  3. 3.
    Dandona, P., A. Aljada, and A. Bandhopadhyay. 2004. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25:4–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Festa, A., et al 2000. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42–47.PubMedGoogle Scholar
  5. 5.
    Steven, J. L., E. Shoelson, and A. B. Goldfine. 2006. Inflammation and insulin resistance. J. Clin. Invest. 116:1793–1801.CrossRefGoogle Scholar
  6. 6.
    Cancello, R., C. Henegar, N. Viguerie, S. Taleb, C. Poitou, C. Rouault, M. Coupaye, V. Pelloux, D. Hugol, J. L. Bouillot, A. Bouloumie, G. Barbatelli, S. Cinti, P. A. Svensson, G. S. Barsh, J. Zucker, A. Basdevant, D. Langin, and K. Clement. 2005. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery induced weight loss. Diabetes 54:2277–2286.PubMedCrossRefGoogle Scholar
  7. 7.
    Clement, K., N. Viguerie, C. Poitou, C. Carette, V. Pelloux, C. A. Curat, A. Sicard, S. Rome, A. Benis, J. D. Zucker, H. Vidal, M. Laville, G. S. Barsh, A. Basdevant, V. Stich, R. Cancello, and D. Langin. 2004. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J. 18:1657–1669.PubMedCrossRefGoogle Scholar
  8. 8.
    Bizzi, A., A. M. Codegoni, and S. Garattini. 1964. Salicylate, a powerful inhibitor of free fatty acid release. Nature 204:1205.PubMedCrossRefGoogle Scholar
  9. 9.
    Zu, L., et al. 2008. Salicylate blocks lipolytic actions of tumor necrosis factor-α in primary rat adipocytes. Molecular Pharmacology Fast Forward 73:215–223.Google Scholar
  10. 10.
    Schonhofer, P. S., J. Sohn, H. D. Peters, and V. Dinnendahl. 1973. Effects of sodium salicylate and acetylsalicylic acid on the lipolytic system of fat cells. Biochem. Pharmacol. 22(5):629–637.PubMedCrossRefGoogle Scholar
  11. 11.
    Shoelson, S. E., J. Lee, and M. Yuan. 2003. Inflammation and the IKKb/IjB/NF-jB axis in obesity- and diet-induced insulin resistance. Int. J. Obes. 27:49–52.CrossRefGoogle Scholar
  12. 12.
    Grimble, R. F. 2002. Inflammatory status and insulin resistance. Curr. Opin. Clin. Nutr. Metab. Care 5:551–559.PubMedCrossRefGoogle Scholar
  13. 13.
    Wellen, K. E., and G. S. Hotamisligil. 2005. Inflammation, stress, and diabetes. J. Clin. Invest. 115:1111–1119.PubMedGoogle Scholar
  14. 14.
    Harkins, J. M., N. Moustaid-Moussa, and Y.-J. Chung. 2004. Expression of interleukin-6 is greater in preadipocytes than in adipocytes of 3T3-L1 cells and C57BL/6J and ob/ob mice. J. Nutrition 134:2673–2677.Google Scholar
  15. 15.
    Fasshauer, M., S. Kralisch, L. M. U. Klier, M. Bluher, J. Klein, and R. Paschke. 2003. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 301:1045–1050.PubMedCrossRefGoogle Scholar
  16. 16.
    Ma, F. 2007. gp130 receptor ligands as potential therapeutic targets for obesity. J. Clin. Invest. 117:841–849.CrossRefGoogle Scholar
  17. 17.
    Tilg, H., and A. R. Moschen. 2008. Inflammatory mechanisms in the regulation of insulin resistance. Mol. Med. 14(3–4):222–231.PubMedGoogle Scholar
  18. 18.
    Liang, C.-P., S. Han, T. Senokuchi, and A. R. Tall. 2007. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ. Res. 100:1546–1555.PubMedCrossRefGoogle Scholar
  19. 19.
    Shi, H., M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116:3015–3025.PubMedCrossRefGoogle Scholar
  20. 20.
    Hotamisligil, G. S., P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman. 1995. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 95(5):2409–2415.PubMedCrossRefGoogle Scholar
  21. 21.
    Ajuwon, K. M., and M. E. Spurlock. 2005. Adiponectin inhibits LPS-induced NF-kappa B activation and IL-6 production and increases PPAR-gamma expression in adipocytes. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288:R1220–R1225.PubMedGoogle Scholar
  22. 22.
    Ye, J. 2008. Regulation of PPAR-gamma function by TNF-a. Biochem. Biophys. Res. Commun. 374:405–408.PubMedCrossRefGoogle Scholar
  23. 23.
    Kusminski, C. M., P. G. McTernan, and S. Kumar. 2005. Role of resistin in obesity, insulin resistance and Type II diabetes. Clin. Sci. (Lond.). 109:243–256.Google Scholar
  24. 24.
    Muse, E. D., T. K. Lam, P. E. Scherer, and L. Rossetti. 2007. Hypothalamic resistin induces hepatic insulin resistance. J. Clin. Invest. 117:1670–1678.PubMedCrossRefGoogle Scholar
  25. 25.
    Zur, E. W. 1876. Therapie des diabetes mellitus, insbesondere über die Anwendung des salicylsauren Natron bei demselben. Berliner Klinische Wochenschrift. 13:337–340.Google Scholar
  26. 26.
    Yin, M. J., Y. Yamamoto, and R. B. Gaynor. 1998. The antiinflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77–80.PubMedCrossRefGoogle Scholar
  27. 27.
    Wellen, K. E., and G. S. Hotamisligil. 2003. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112:1785–1788.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Pharmacology of Chinese Materia MedicaChina Pharmaceutical UniversityNanjingPeople’s Republic of China

Personalised recommendations